Senti Bio Extends Cash Runway to 2026 with Additional $11.5 Million Financing
ByAinvest
Monday, Jan 6, 2025 9:02 am ET1min read
EFSC--
NEA--
SNTI--
Senti Bio has raised an additional $11.5 million in financing, bringing the total raised in the round to $47.6 million. The additional funding will extend the company's cash runway guidance into 2026 and will be used to fund the development of its SENTI-202 program and manufacturing ramp-up, as well as other research and development activities. The financing was led by Celadon Partners and included participation from New Enterprise Associates (NEA), Leaps by Bayer, and other institutional and accredited investors.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet